Dose-response relationship: Relevance for clinical use;Dosis-Wirkungs-Beziehung: Relevanz fur die arztliche Praxis

Medizinische Klinik

Volumn 95, Issue SUPPL. 1, 2000, Pages 9-14

  Klinkhardt, Ute ^a   Harder, Sebastian ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b NONE

Author keywords

Dose finding studies; Dose response relationship; Drug development

Indexed keywords

ARTICLE; DOSE RESPONSE; DRUG USE; HUMAN; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; CLINICAL TRIAL; DRUG SURVEILLANCE PROGRAM; REVIEW; TREATMENT OUTCOME;

DRUG;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME;

EID: 0034186141     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Carlsen JE, Kober L, Torp-Pedersen C, et al. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 1990;300: 975-8.
2. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-o-methyltransferase inhibitor tolcapone during first administration in humans. Clin Pharm Ther 1995;57: 508-17.
3. Elmfeldt D, George M, Hübner R, et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent and hypertensive effect. J Hum Hypertens 1997;11:Suppl 2:S49-53.
4. Godwey CW. Aguide to the pharmacology of placebos. Can Med Assoc J 1983;128:921-5
5. Greenwood DT, Todd AH. From laboratory to clinical use. In: Johnson FN, Johnson S. Clinical trials. London-Edinburgh: Blackwell, 1977.
6. Harder S. Methodische Grundlagen des Wirksamkeitsnachweises. In: Hasford J, Staib AH, Hrsg. Arzneimittelprüfungen und Good Clinical Practice. München: MMW-Verlag, 1994:23-31.
7. Harder S, Thürmann PA, Thierolf C. et al. Prescription of cardiovascular drugs in ambulatory care: A survey of ambulatory patients in a German university hospital, Int J Clin Pharm Ther 1998;36:195-201.
8. Herxheimer A. How much drug in the tablet? Lancet 1991;337:346-8.
9. Markham A, Goa KL, Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311.
10. Pöch G, Juan H. Allgemeine Pharmakodynamik. Stuttgart: Thieme, 1985.
11. Pool JL, Guthrie RM, Littlejohn TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11:462-70.
12. Schmidt R. Dose-finding studies in clinical drug development. Eur J Pharmacol 1988;34:15-9.
13. Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharm Ther 1989;46:63-77.